#plasticell | Explore Tumblr posts and blogs

kimludcom · 4 months ago

Link

SPECIFICATIONSBrand Name: KLASSNUMOrigin: Mainland ChinaApplicable Scenarios: PARTYGender: WOMENStyle type: special-shapedProduct Type: Fashion SunglassesDepartment Name: ADULTFrame Material: plasticElement type: PARTYLenses Optical Attribute: Anti-reflectiveLenses Optical Attribute: UV400Model Number: Funny Mosaic Sun

0 notes

reportsanddata · 3 years ago

Text

Induced Pluripotent Stem Cells Market Size, Revenue Growth Factors & Trends, Key Player Strategy Analysis, 2020–2027

Global Induced Pluripotent Stem Cells Market report published by Reports and Data offers a comprehensive analysis of the Induced Pluripotent Stem Cells market with regards to market share, market size, revenue growth, trends and demands, drivers and restraints, competitive scenario, business landscape, and regional bifurcation. The report has been generated by extensive secondary research with updated and latest information of the global Induced Pluripotent Stem Cells market further validated and verified by the industry experts and professionals. The report also offers forecast estimation about segments and sub-segments expected to show lucrative growth over the forecast period. The report, additionally, offers a comprehensive SWOT analysis and Porter’s Five Forces analysis to offer a better understanding of the competitive landscape of the industry.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3551

The report focuses on the comprehensive analysis of the competitive landscape along with detailed company profiles, market share, product portfolio, financial standings, market reach, global position, and strategic business expansion plans.

Some of the players profiled in the report are

Thermo Fisher Scientific, Allele Biotechnology and Pharmaceuticals Inc., ABM (Applied Biological Materials Inc.), Addgene, Axol Bioscience, Cell Signaling Technology, Bluerock Therapeutics, Alstem LLC, Applied Stemcell Inc., ATCC, Creative Bioarray, Bristol-Myers Squibb, Bio-Techne, Reprocell Group Co., Primorigen Biosciences, ID Pharma Co. Ltd., Megakaryon Corp., FUJIFILM Cellular Dynamics, Inc., Waisman Biomanufacturing, Roslin Cell Sciences, Opsis Therapeutics, Corning Life Sciences, Fate Therapeutics, Genecopoeia, Gentarget Inc., Viacyte Inc., Ncardia, Invivogen, Lonza Group Ltd., Plasticell Ltd., Stemcell Technologies, Newcells Biotech, Orig3N Inc., Peprotech, Promega Corp., Promocell Gmbh, Qiagen N.V., System Biosciences Inc., Reprocell Inc., Sciencell Research Laboratories, MilliporeSigma, and Takara Bio Usa Inc.

The report sheds light on mergers and acquisitions, joint ventures, collaborations, partnerships, and product launches among others. It also discusses in detail the technological advancements, product developments, and research and development activities of each key company.

Further the report segments the Induced Pluripotent Stem Cells market on the basis of product types, applications, end-uses, and regions. The report discusses in detail the key factors influencing revenue growth of the segments and market growth in key regions. It also discusses economic growth, technological advancement, and presence of key players in each major geographical region.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3551

Derived Cell Type Outlook (Revenue in USD Million; 2017–2027)

Amniotic Cells

Fibroblasts

Keratinocytes

Hepatocytes

Others

Application Outlook (Revenue in USD Million; 2017–2027)

Drug Development

Toxicity Testing

Regenerative Medicine

Academic

End-User Outlook (Revenue in USD Million; 2017–2027)

Hospitals

Research Institutions

Market Segmentation by Regions:

· North America (U.S.A., Canada)

· Europe (U.K., Italy, Germany, France, Rest of Europe)

· Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

· Latin America (Chile, Brazil, Argentina, Rest of Latin America)

· Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

To know more about the report @ https://www.reportsanddata.com/report-detail/induced-pluripotent-stem-cells-market

Key Points Covered in the Report:

· Key insights into the latest growth trends, developments, technological and product advancements, and research and development scenario

· Analysis of micro- and macro-economic factors and regulatory framework

· In-depth evaluation of factors such as cost, capacity, rates of production and consumption, gross revenue, profit margin, demand and supply ratio, import/export, market share, market size, and market trends

· SWOT analysis, Porter’s Five Forces Analysis, investment return analysis, and feasibility analysis to offer a comprehensive view of the competitive landscape

· Strategic recommendations to established market players and new entrants to overcome limitations and entry-level barriers in the global market landscape

· A comprehensive 8 year assessment of the global Induced Pluripotent Stem Cells market for the period 2021-2027

· Analysis of market drivers, restraints, challenges, limitations, threats, growth prospects and opportunities

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/3551

Thank you for reading the report. The report can be customize as per requirements of the clients. For further information or query about customization, please reach out to us and we will offer you the report best suited for your needs.

0 notes

ssvauto · 5 years ago

Photo

K2 Solutie Dezghetat Pabriz -70C Alaska Max 770ML ❕❕❕PRET SPECIAL: 17 LEI❕❕❕ ▪️Soluţie extrem de eficientă pentru dezgheţat parbrize și geamuri. Nu afectează plasticele, chederele sau vopseaua. Temperatura la care acţionează coboară până la -70°C. CUM SĂ UTILIZAȚI: ▪️Pulverizati cu solutie pe stratul de gheata. ▪️După ce gheața sa topit, stergeti imediat cu o cârpă sau folositi ștergătoarele. ▪️Pentru a elimina stratul de gheață mai gros folositi un razuitor. https://www.instagram.com/p/B5KbK7OHwjA/?igshid=d789al8ax6x7

0 notes

healthcaremarket242-blog · 6 years ago

Text

Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2018-2026

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.

Rising incidence of leukemia and lymphoma and continuous research on hematopoietic stem cells are expected to drive market growth

As per 2017 report by Leukemia and Lymphoma Society, the U.S. alone is expected to account for a prevalence of 8,16,834 and incidence of 80,500 for lymphoma. Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players.

Request For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1250

Global Hematopoietic Stem Cell Transplantation Market Taxonomy

On the basis of indication:

Leukemia, Lymphatic disorder, Myeloma

Other non-malignant disorders (thalassemia, sickle cell anemia, Osteoporosis, Immunodeficiency syndrome)

On the basis of application:

Peripheral blood cells, Bone marrow, Umbilical cord blood

Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN.

In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017.

Important players present in the hematopoietic stem cell transplantation market

Major players operating in the hematopoietic stem cell transplantation market include Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.

Click To Read More On Hematopoietic Stem Cell Transplantation (HSCT) Market

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

#Hematopoietic Stem Cell Transplantation (HSCT) Market #Hematopoietic Stem Cell Transplantation (HSCT) Market Share #Hematopoietic Stem Cell Transplantation (HSCT) Market Size

0 notes

pharmaphorumuk · 6 years ago

Text

Talks from the MHRA, Innovate UK, Plasticell and more

The lengthening shadow of increase in health spending in the coming years is sharpening the minds of legislators, regulators and payers alike. The growing time-to-market, the rising costs in development of novel medicines, as well as the more basic drive to be ‘ahead of the game’, forces the industry and the legislators to rethink basic postulates of drug development.

The global regulatory environment is undergoing major reshape, allowing patients early access to breakthrough technology and allowing industry opportunities for early access to market. Patient advocacy groups are incorporated in legislation discussions, and are brought into the room where industry and regulator discuss the clinical development of novel therapies.

Earlier access to market allows smaller commercial companies to jump through the ‘death valley’ of drug development, reduce the traditional high investment risks in biotechnology, and ultimately provide more competition to big and well-established pharma giants.*

MHRA:

These regulatory issues within the industry will be addressed by the MHRA this October. Janet Glassford, Senior Quality Assessor (Biologicals), MHRA will be presenting a UK and EU regulatory affairs perspective.

The MHRA will look into the impact of Brexit and further initiatives within the cell and gene space. The presentation will look into a way of designing clinical trials in a way that comes up with the evidence regulators need to accelerate ATMPs. Also, what support is available for companies who are early in the development process, and ensuring safety while reducing the cost of development, by working together with regulators to make the approval process more efficient.

Innovate UK:

With the event being held in the United Kingdom (UK), this a great location for the inaugural conference as the UK is investing £3m ($4m) to build a workforce capable of delivering cell and gene therapies to patients at commercial scales. Innovate UK, a nongovernmental public funding body, is making the money available to equip the UK to handle commercial cell and gene therapies. This has enabled more investments and differentiated the UK from the EU companies. The UK has already made major commitments to the development of such advanced medicines, but commercial products present a fresh challenge.

Ian McKay, Innovation Lead, Advanced Therapies, Innovate UK, will be speaking at the conference about supporting advanced therapies – the Innovate UK perspective.

Plasticell:

Plasticell is a biotechnology company developing therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Using combinatorial screening technology, enables Plasticell to test large numbers of cell culture variables to derive optimal laboratory protocols for any given outcome in cell biology, including cell expansion and differentiation, gene transduction and protein production, as well as the provision of human cells for drug screening.

Plasticell collaborates with leading universities and industry partners to facilitate discovery and improve product manufacturing in a variety of high value areas such as cell therapy, gene therapy, cancer immunotherapy and drug discovery.

Yen Choo, Founder and Executive Chairman, Plasticell will be presenting an opening address on the advances in cell therapy process development and optimisation at Plasticell. He will discover the development of their combinatorial screening product. the expansion of hematopoietic stem cells from cord blood for allogeneic transplantation and enhancement of viral transduction efficiency for autologous gene therapy to treat rare diseases. For further details, download your copy of the agenda.

Download the full interview online in the download centre

Further information is available at: www.cellandgeneconference.com/phpr

SMi Presents the Launch of: Cell & Gene Therapy 2018 Date: 10th – 11th October 2018 Workshops: 9th October 21018 Location: Copthorne Tara Hotel, London UK Website: www.cellandgeneconference.com/phpr

Source: https://bit.ly/2mMtuDt

—end—

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: [email protected]

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

The post Talks from the MHRA, Innovate UK, Plasticell and more appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/partner-content/talks-from-the-mhra-innovate-uk-plasticell-and-more/

0 notes

saojip13 · 5 years ago

Text

Stem Cell Therapy Market Players: Cytori Therapeutics Inc., Fibrocell Science, Cellartis AB, BioTime, GE Healthcare, etc

Stem cell therapy involves use of stem cells to treat various diseases or disorders. Stem cells are fundamental for every tissue and organ in the body. Stem cells are indistinguishable biological cells that are able to differentiate into specialised cells (liver cells, cardiac cells etc.) and can renew itself (through mitosis) to produce more stem cells. Stem cells have the ability to replicate, repair, and replace other damaged tissues in the human body. In addition, stem cell based therapies are also used to treat several chronic diseases such as blood disorders, cancer and others.

Get a Sample Copy of this Report @ https://www.alexareports.com/report-sample/170621

Growing awareness about the potency of stem cells in disease management, development of advanced gene based analysis techniques and increase in public, private investments in stem cell research are acting as growth drivers for stem cell therapy market. In addition, identification of new stem cell lines and development of infrastructure for stem cell banking & processing are propelling the growth of the global stem cell therapy market. However, ethical issues involved in stem cells research such as destruction of human embryos, religious beliefs are considered as road blocks for adaptation of stem cell therapy by patients. However, stringent regulations to conduct trials on humans, high-cost of research and storage of stem cells are some restraining factors for stem cell therapy market.

Stem cell therapy market has been segmented on the basis of treatment mode, cell types, application, technology, and end-user

Based on treatment, stem cell therapy market is segmented into

Allogeneic Autologous

Based on cell type, stem cell therapy market is segmented into

Adult Stem cells Induced Pluripotent Stem cells Human Embryonic Stem Cells Others

Based on technology, stem cell therapy market is segmented into

Cell Production Cell Acquisition Cryopreservation

Based on end-user, stem cell therapy market segmented into

Hospitals Ambulatory Centers Research Centers

Grab amazing discount here @ https://www.alexareports.com/check-discount/170621

Stakeholders in stem cell therapy such as academic institutions and research firms are collaborating in development of stem cell therapy and industry collaborations also projecting enormous growth of stem cell therapy market. For instance, in November 2015, Cellular Dynamics International, Inc. (FUJIFILM) collaborated with Roche to supply iCell (CDI’s induced pluripotent stem cell derived) products that enables in identification of novel drug candidates at the early stages of drug discovery. Similarly, in May 2018, Magenta Therapeutics, entered into strategic partnership with Be The Match BioTherapies, to improve and expand the use of curative stem cell transplantation.

Geographically stem cell therapy market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Among the regions, North America dominates global stem cell therapy market due to factors such as increasing prevalence of chronic diseases, growing awareness, and rising investment in research and development activities. In Asia Pacific region, due to the favourable government policies, development healthcare infrastructure, industry collaborations in research and developments expected to boost stem cell therapy market. For instance, in April 2018, Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (A*STAR), Singapore, and the Nanyang Technological University (NTU), Singapore, to progress its therapeutic stem cell pipeline.

Some of the players in stem cell therapy market are Cytori Therapeutics Inc. (U.S.), Fibrocell Science (U.S.), Cellartis AB (Cellectis) (France), BioTime, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), STEMCELL Technologies Inc. (Canada), Fujifilm Holdings Corporation (Japan), Vericel Corporation (Aastrom Bioscience) (U.S.), Brainstorm cell therapeutics (U.S.), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), Celgene Corporation (U.S.), and Osiris Therapeutics, Inc. (U.S.) to name a few.

To Enquire About This Comprehensive Report@ https://www.alexareports.com/send-an-enquiry/170621

In February 2016, Mesoblast Limited’s licensee in Japan, JCR Pharmaceuticals Co. Ltd., launched “TEMCELL HS Inj”, the first allogeneic cell therapy to be fully approved in Japan, for the treatment of acute graft versus host disease in children and adults

Details of the market study:

Historical Data: 2014 & 2017

Base Year: 2018

Forecasts: 2019-2025

CAGR: 2019-2025

Market trend analysis in terms of drivers, restraints and opportunities

Industry analysis using Porter’s, PESTEL and SWOT

Market players analysis in terms of company’s overview, financial performance, product/service benchmarking and strategic initiatives taken up by them

#Stem Cell Therapy Market

0 notes

expertofmarketinsights-blog · 6 years ago

Text

Hematopoietic Stem Cell Transplantation (HSCT) Market Upcoming Trends, Demand and Analysis Till 2026

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body. Click To Read More on Hematopoietic Stem Cell Transplantation (HSCT) Market.

Rising incidence of leukemia and lymphoma and continuous research on hematopoietic stem cells are expected to drive market growth

As per 2017 report by Leukemia and Lymphoma Society, the U.S. alone is expected to account for a prevalence of 8,16,834 and incidence of 80,500 for lymphoma. Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players.

However, high costs associated with hematopoietic stem cell transplantation procedures are expected to hinder growth of the market. Other factors such as difficulty in finding a donor for allogeneic transplantation, technological barriers (currently used culture technologies, point of care delivery, and lack of analytical assay), and side effects such as graft vs. host disease, are also expected to slow down growth of the hematopoietic stem cell transplantation market.

Important players present in the hematopoietic stem cell transplantation market

Major players operating in the hematopoietic stem cell transplantation market include Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.

Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1250

In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017.

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Hematopoietic Stem Cell Transplantation (HSCT) Market #Hematopoietic Stem Cell Transplantation (HSCT) Market Size #Hematopoietic Stem Cell Transplantation (HSCT) Market Share #Hematopoietic Stem Cell Transplantation (HSCT) Market Outlook

0 notes

hewayasin · 6 years ago

Text

The Ten Tee Commandments

I am a child of the 90’s and the soundtrack to my teen years was the Life After Death double CD. The Notorious B.I.G was my idol and the idea for the name ‘Giddimint‘ came from a Biggie interview I had on heavy rotation on my iPod at the time. That said, the “Ten Crack Commandments” spoke to me specially because BIG was giving straight knowledge on the track, knowledge which I have found…

View On WordPress

#Entrepreneurship #Giddimint #Streetwear #T-Shirts

0 notes

kimludcom · 4 months ago

Link

SPECIFICATIONSBrand Name: KLASSNUMOrigin: Mainland ChinaApplicable Scenarios: PARTYGender: WOMENStyle type: special-shapedProduct Type: Fashion SunglassesDepartment Name: ADULTFrame Material: plasticElement type: PARTYLenses Optical Attribute: Anti-reflectiveLenses Optical Attribute: UV400Model Number: Funny Mosaic Sun

0 notes

coolvoidunknown-blog · 7 years ago

Text

Artificial Blood Market

Artificial Blood Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Global Artificial Blood Market: By Product Type (Hemoglobin-Based Oxygen Carriers, Perflurocarbon-Based Products, Recombinant Factors, Synthetic Platelets, Plasma Expanders, Others),By Application (Traumatic Injuries, Blood Disorders, Anemia, Surgeries, Others), By Distribution Channel(Hospitals, Clinics, Blood Banks), and Geography –Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Market Outline: Artificial Blood Market

Artificial blood or synthetic blood and blood products are the alternatives to the blood transfusion to replace the blood. It fulfills and replicates the normal functions of the body. Artificial blood is infused in the traumatic injuries and other disease conditions for the transportation of carbon di oxide and oxygen across the body. Moreover, scientists are focusing on the development of artificial blood due to inadequate number of blood donors leads to shortage of blood. However, there are adverse effects associated with the artificial blood such as hemoglobin based blood substitute might increase the occurrence of heart attacks.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/artificial-blood-market/#ulp-4H8Z4LpNMLEuOnnx

Market Dynamics: Artificial Blood Market

Drivers:

· Increase in the prevalence of anemia and traumatic injuries

· Rise in R&D for the innovation of newer products

· Growing number of surgeries combined with decrease in number of blood donors

Restraints:

· Lower shelf-life and instability of artificial blood

· Adverse effects associated with artificial blood substitutes

· Stringent regulatory guidelines for product approval

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/artificial-blood-market/#ulp-c654SbFYO64MsOhu

Market Scope: Artificial Blood Market

Artificial blood products market is segmented on the basis of product type, application, distribution channel, and region

Based on the product type, artificial blood market is segmented into the following:

· Hemoglobin-Based Oxygen Carriers

· Perflurocarbon-Based Products

· Recombinant Factors

· Synthetic Platelets

· Plasma Expanders

· Others

Based on the application, artificial blood market is segmented into the following:

· Traumatic Injuries

· Blood Disorders

· Anemia

· Surgeries

· Others

Based on the distribution channel, artificial blood market is segmented into the following:

· Hospitals

· Clinics

· Blood Banks

Based on the region, artificial blood market is segmented into the following:

· North America

· Europe

· Asia Pacific

· Latin America

· Middle East and Africa

Competition Assessment: Artificial Blood Market

Some of the players in the global artificial blood include:

· Alpha Therapeutic Corp (U.S.)

· FluorO2 Therapeutics (U.S.)

· Plasticell Limited (U.K.)

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/artificial-blood-market/#ulp-14mlyhjMGhVjZqa3

Notable Market Developments: Artificial Blood Market

· In April 2017, Plasticell collaborated with Kings College London to progress the preclinical trials of artificial blood platelet product, prepared from pluripotent stem cells

Key Features of the Report:

· The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)

· The report covers in-detail insights about the competitor’s overview, company share analysis, key marketdevelopments, and their key strategies

· The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

· The report tracks recent innovations, key developments and startup’s details that are actively working in the market

· The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

· The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/artificial-blood-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: [email protected]

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

0 notes

stiri-noi · 4 years ago

Text

Ce s-ar întâmpla dacă oamenii ar dispărea?

Momentan, oamenii sunt specia dominantă de pe Terra.

Homo sapiens este specia care domină în acest punct al istoriei planeta, capacitatea noastră de a ne extinde, dar și de a transforma radical mediul în care trăim ne oferă un avantaj considerabil în fața celorlalte specii. Adesea, când ne gândim la sfârșitul lumii, ne imaginăm sfârșitul întregii planete sau chiar al întregului Univers. Cu toata acestea, în ciuda poziției nostre în lanțul trofic, trebuie să luăm în calcul posibilitatea ca viața pe Terra să continue fără noi.

Dacă acceptăm această posibilitate a unui pământ fără oameni, atunci trebuie să ne punem, în mod evident, întrebări legate de modul în care Terra ar putea arăta. Dacă ne uităm la ruinele orașului mayaș Tikal observăm un adevăr cât se poate de dur: natura face o treabă foarte bună în ceea ce privește acoperirea urmelor existenței noastre. Acest oraș a fost părăsit în urmă cu 1.000 de ani și în momentul descoperirii era acoperit de o junglă extrem de deasă.

O lume fără noi

Alan Weisman, autorul cărții The World Without us, a petrecut mai mulți ani în căutarea unor răspunsuri legate de modul în care ar putea evolua planeta în absența noastră. Pentru a obține aceste răspunsuri el a stat de vorbă cu o serie de experți din o gamă largă de domenii.

Există mai multe teorii care ar putea explica ce ar putea duce umanitatea la dispariție și este puțin probabil să dispărem cu toții într-o clipă. Cu toate acestea, a ne imagina eradicarea bruscă și completă de pe planetă – poate printr-un virus specific speciei noastre, este cel mai la îndemână mod de a explora ce ar putea întâmpla dacă oamenii dispărea de pe planetă.

Dispariția oamenilor ar avea efecte majore asupra orașelor, unde se vor desfășura unele dintre cele mai dramatice și imediate schimbări, datorită lipsei de întreținere umană. Fără oameni să folosească pompe care adună precipitațiile și apele subterane în creștere, metroul unor orașe uriașe, precum Londra și New York, s-ar inunda în câteva ore de la dispariția noastră. Weisman explică faptul că unii ingineri i-au spus că rețelele de metrou ar avea nevoie de doar 36 de ore pentru a fi complet blocate de ape.

Centralele nucleare, termonucleare și exploatările de gaze naturale și petrol reprezintă un pericol chiar și în prezent, sub supravegherea umană, cu toate acestea, dispariția noastră ar putea agrava și mai mult situația. Cel mai probabil, aceste eveniment ar putea fi urmat de o serie de dezastre nucleare, incendii și scurgeri de țiței.

Orașe se ridică și cad, plasticul persistă

După cum arată studiile, plasticul are șanse foarte mari să supraviețuiască foarte mult, chiar și după dispariția noastră, iar asta s-ar putea transforma într-un pericol și mai mare în absența noastră. Astfel, scurgerile de țiței ar ajunge să fie „rezolvate” de către planete și bacterii. Dar, din nefericire, plasticele vor supraviețui câteva sute de ani, iar efectele asupra faunei și florei sunt greu de aproximat.

Apa care circulă subteran orașelor va coroda structurile metalice care ținea străzile deasupra sistemelor de transport subterane și căile de comunicații s-ar prăbuși, transformate brusc în râuri, a explicat Weisman. Iernile succesive, fără ca oamenii să se ocupe de mentenanță, ar face ca trotuarele să se crape, oferind noi nișe din care să încolțească semințele. În timp, aceste semințe se vor dezvolta în copaci care continuă distrugerea treptată a trotuarelor și drumurilor. Același lucru s-ar întâmpla și cu podurile, împreună cu degradarea generală, acest lucru ar putea demola aceste structuri în câteva sute de ani.

Pe parcursul a sute de ani, pe măsură ce clădirile vor suferi daune susținute din cauza eroziunii și a incendiilor, acestea se vor prăbuși, a spus el. Primele care se vor răsturna vor fi structurile moderne din sticlă și metal, afectate de rugină.

Incendiile vor crea o mulțime de materiale carbonizate care vor cădea pe străzi, ceea ce se va transforma în nutrienți pentru alimentarea vieții biologice. Străzile se vor converti în pășuni mici și păduri care se vor dezvolta în decurs de 500 de ani.

O reacție în lanț

Dispariția speciei noastre va deschide posibilitatea unei vieții mai bune pentru alte specii, astfel, Weisman estimează un efect de cascadă. „Odată ce insectele se vor descurca mai bine, atunci plantele se vor descurca mult mai bine, și apoi păsările”.

Această tranziție va precipita o încuraja a biodiversității la scară globală. Cercetătorii care au creat modele ale diversității megafaunei, precum leii, elefanții, tigrii, rinocerii și urșii, au dezvăluit că lumea era deosebit de bogată în aceste specii la un anumit moment dat. Dar asta s-a schimbat atunci când oamenii au început să se răspândească pe planetă, vânând aceste animale și invadând habitatele lor.

În cele din urmă, planeta ar putea deveni mai diversă, dar nu putem uita de efectele schimbărilor climatice, probabil cel mai semnificativ impact al umanității asupra planetei. Weisman constată incertitudinea inerentă în a face predicții utile despre ceea ce se va întâmpla. De exemplu, în cazul în care există explozii la fabricile industriale sau la puțurile de petrol sau gaz care continuă să ardă mult după ce am dispărut, cantitățile uriașe de dioxid de carbon produse ar duce la o creștere continuă a temperaturilor.

Așa cum este, nivelurile actuale de CO2 din atmosfera noastră vor persista de-a lungul a mii de ani înainte de a fi îndepărtate complet din atmosferă. Și dacă marea își atinge capacitatea maximă de absorbție, o cantitate mare de carbon rămâne suspendată în atmosferă. Încălzirea continuă rezultată va duce la topirea calotelor de gheață polară și la eliberarea și mai multor gaze cu efect de seră de la înmuierea permafrostului. Aceasta se va transforma într-o buclă de feedback continuă, a schimbărilor climatice. Ce înseamnă asta? Că problemele pe care le avem acum vor persista mult după dispariția noastră.

Citește și:

Cercetătorul care își petrece tot timpul încercând să prezică sfârșitul lumii. Ce spune despre pandemia actuală

Savanţii îi ironizează pe adepţii teoriilor conspiraţiilor care susţin că Nibiru va aduce sfârşitul lumii

Stephen Hawking, celebrul fizician care a revoluţionat astrofizica, prezice că sfârşitul lumii este mai aproape decât credem

Raport dramatic al Naţiunilor Unite: Pentru a se evita o catastrofă trebuie scăzute drastic emisiile de carbon. Cu cât va creşte nivelul oceanelor până în anul 2100

Articolul Ce s-ar întâmpla dacă oamenii ar dispărea? apare prima dată în Descopera.ro.

#Ce s-ar întâmpla dacă oamenii ar dispărea?

0 notes

ssvauto · 5 years ago

Photo

Pachet 6 Buc Sonax Solutie Curatat Bord Xtreme 500ML 283241 - Pret special: 260 Lei ! ! ! - Descriere: Sonax Xtreme Cockpit Cleaner - Solutie Curatare Plastice curata si protejeaza toate plasticele interioare ale unui autovehicul. Sonax Xtreme Cockpit Cleaner - Solutie Curatare Plastice este o solutie cu efect antistatic. Reda culoarea mata a plasticelor. Lasa un miros proaspat. Nu contine solventi sau silicon. - Continut: 500ML (la SSV AUTO) https://www.instagram.com/p/ByR-Ri7IlH4/?igshid=w5w089fehhn9

0 notes

healthcaremarket242-blog · 6 years ago

Text

Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2018-2026

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.

Rising incidence of leukemia and lymphoma and continuous research on hematopoietic stem cells are expected to drive market growth

As per 2017 report by Leukemia and Lymphoma Society, the U.S. alone is expected to account for a prevalence of 8,16,834 and incidence of 80,500 for lymphoma. Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players.

Request For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1250

Global Hematopoietic Stem Cell Transplantation Market Taxonomy

On the basis of indication:

Leukemia, Lymphatic disorder, Myeloma

Other non-malignant disorders (thalassemia, sickle cell anemia, Osteoporosis, Immunodeficiency syndrome)

On the basis of application:

Peripheral blood cells, Bone marrow, Umbilical cord blood

Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN.

In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017.

Important players present in the hematopoietic stem cell transplantation market

Major players operating in the hematopoietic stem cell transplantation market include Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.

Click To Read More On Hematopoietic Stem Cell Transplantation (HSCT) Market

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

#Hematopoietic Stem Cell Transplantation (HSCT) Market #Hematopoietic Stem Cell Transplantation (HSCT) Market Share #Hematopoietic Stem Cell Transplantation (HSCT) Market Size #Hematopoietic Stem Cell Transplantation (HSCT)

0 notes

pharmaphorumuk · 6 years ago

Text

An experimental gene therapy for DMD shows positive results

SMi are delighted to welcome the expertise from a senior panel of big biotech’s and pharma organisations, as well as regulatory bodies, at the inaugural Cell & Gene Therapy 2018 conference, taking place this October in the City of London, UK.

Did you know… the global gene therapy market is forecasted to hit $363 million by 2022.